PMID- 36627305 OWN - NLM STAT- MEDLINE DCOM- 20230117 LR - 20240210 IS - 2052-4463 (Electronic) IS - 2052-4463 (Linking) VI - 10 IP - 1 DP - 2023 Jan 10 TI - InvitroSPI and a large database of proteasome-generated spliced and non-spliced peptides. PG - 18 LID - 10.1038/s41597-022-01890-6 [doi] LID - 18 AB - Noncanonical epitopes presented by Human Leucocyte Antigen class I (HLA-I) complexes to CD8(+) T cells attracted the spotlight in the research of novel immunotherapies against cancer, infection and autoimmunity. Proteasomes, which are the main producers of HLA-I-bound antigenic peptides, can catalyze both peptide hydrolysis and peptide splicing. The prediction of proteasome-generated spliced peptides is an objective that still requires a reliable (and large) database of non-spliced and spliced peptides produced by these proteases. Here, we present an extended database of proteasome-generated spliced and non-spliced peptides, which was obtained by analyzing in vitro digestions of 80 unique synthetic polypeptide substrates, measured by different mass spectrometers. Peptides were identified through invitroSPI method, which was validated through in silico and in vitro strategies. The peptide product database contains 16,631 unique peptide products (5,493 non-spliced, 6,453 cis-spliced and 4,685 trans-spliced peptide products), and a substrate sequence variety that is a valuable source for predictors of proteasome-catalyzed peptide hydrolysis and splicing. Potential artefacts and skewed results due to different identification and analysis strategies are discussed. CI - (c) 2023. The Author(s). FAU - Roetschke, Hanna P AU - Roetschke HP AUID- ORCID: 0000-0001-7272-6677 AD - Max-Planck-Institute for Multidisciplinary Sciences (MPI-NAT), 37077, Gottingen, Germany. AD - Centre for Inflammation Biology and Cancer Immunology (CIBCI) & Peter Gorer Department of Immunobiology, King's College London (KCL), SE1 1UL, London, UK. FAU - Rodriguez-Hernandez, Guillermo AU - Rodriguez-Hernandez G AD - Centre for Inflammation Biology and Cancer Immunology (CIBCI) & Peter Gorer Department of Immunobiology, King's College London (KCL), SE1 1UL, London, UK. AD - Francis Crick Institute, NW1 1AT, London, UK. FAU - Cormican, John A AU - Cormican JA AD - Max-Planck-Institute for Multidisciplinary Sciences (MPI-NAT), 37077, Gottingen, Germany. FAU - Yang, Xiaoping AU - Yang X AD - Proteomics Core Facility, James Black Centre, King's College London (KCL), SE5 9NU, London, UK. FAU - Lynham, Steven AU - Lynham S AD - Proteomics Core Facility, James Black Centre, King's College London (KCL), SE5 9NU, London, UK. FAU - Mishto, Michele AU - Mishto M AUID- ORCID: 0000-0003-3042-2792 AD - Centre for Inflammation Biology and Cancer Immunology (CIBCI) & Peter Gorer Department of Immunobiology, King's College London (KCL), SE1 1UL, London, UK. michele.mishto@kcl.ac.uk. AD - Francis Crick Institute, NW1 1AT, London, UK. michele.mishto@kcl.ac.uk. FAU - Liepe, Juliane AU - Liepe J AD - Max-Planck-Institute for Multidisciplinary Sciences (MPI-NAT), 37077, Gottingen, Germany. jliepe@mpinat.mpg.de. LA - eng GR - 29686/CRUK_/Cancer Research UK/United Kingdom PT - Dataset PT - Journal Article DEP - 20230110 PL - England TA - Sci Data JT - Scientific data JID - 101640192 RN - 0 (Histocompatibility Antigens Class I) RN - 0 (Peptides) RN - EC 3.4.25.1 (Proteasome Endopeptidase Complex) SB - IM MH - Humans MH - *CD8-Positive T-Lymphocytes MH - Cytoplasm MH - Histocompatibility Antigens Class I MH - Peptides/chemistry MH - *Proteasome Endopeptidase Complex PMC - PMC9832164 COIS- The authors have no conflicts of interest. EDAT- 2023/01/11 06:00 MHDA- 2023/01/13 06:00 PMCR- 2023/01/10 CRDT- 2023/01/10 23:15 PHST- 2021/08/25 00:00 [received] PHST- 2022/12/01 00:00 [accepted] PHST- 2023/01/10 23:15 [entrez] PHST- 2023/01/11 06:00 [pubmed] PHST- 2023/01/13 06:00 [medline] PHST- 2023/01/10 00:00 [pmc-release] AID - 10.1038/s41597-022-01890-6 [pii] AID - 1890 [pii] AID - 10.1038/s41597-022-01890-6 [doi] PST - epublish SO - Sci Data. 2023 Jan 10;10(1):18. doi: 10.1038/s41597-022-01890-6.